title: Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration.
abstract: To evaluate the potential for an interaction between clarithromycin and loratadine, healthy male volunteers (n = 24) received each of the following regimens according to a randomized crossover design: 500 mg of clarithromycin orally every 12 h (q12h) for 10 days, 10 mg of loratadine orally q24h for 10 days, and the combination of clarithromycin and loratadine. A washout interval of 14 days separated regimens. The addition of loratadine did not statistically significantly affect the steady-state pharmacokinetics of clarithromycin or its active metabolite, 14(R)-hydroxy-clarithromycin. However, the addition of clarithromycin statistically significantly altered the steady-state maximum observed plasma concentration and the area under the plasma concentration-time curve over a dosing interval for loratadine (+36 and +76%, respectively) and for descarboethoxyloratadine (DCL), the active metabolite of loratadine (+69 and +49%, respectively). Clarithromycin probably inhibits the oxidative metabolism of loratadine and DCL by the cytochrome P-450 3A subfamily. Electrocardiograms (n = 12) were obtained over 24-h periods at baseline and steady state (day 10). The mean maximum QTc interval and area under the QTc interval-time curve on day 10 were modestly increased (<3%) from baseline for all three regimens, but no QTc interval exceeded 439 ms for any subject. Elevated steady-state concentrations of loratadine and DCL do not appear to be associated with adverse cardiovascular effects related to prolongation of the QTc interval. Loratadine and clarithromycin were well tolerated, alone and in combination.
authors.affiliation: Abbott Laboratories, Abbott Park, Illinois 60064-3500, USA. robert.a.carr@abbott.com
authors.forename: R A
authors.initials: RA
authors.lastname: Carr
authors.forename: A
authors.initials: A
authors.lastname: Edmonds
authors.forename: H
authors.initials: H
authors.lastname: Shi
authors.forename: C S
authors.initials: CS
authors.lastname: Locke
authors.forename: L E
authors.initials: LE
authors.lastname: Gustavson
authors.forename: J C
authors.initials: JC
authors.lastname: Craft
authors.forename: S I
authors.initials: SI
authors.lastname: Harris
authors.forename: R
authors.initials: R
authors.lastname: Palmer
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D018926:Anti-Allergic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004338:Drug Combinations; D004347:Drug Interactions; D004562:Electrocardiography / Q000187:drug effects; D006801:Humans; D017336:Loratadine / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology; D008297:Male
chemical_list: D018926:Anti-Allergic Agents; D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D017336:Loratadine; D017291:Clarithromycin